Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments.: External Assessment Group Report

Pedro Rafael Saramago Goncalves; Mark Rodgers; Shainur Premji; Noortje Uphoff; Minyue Gao; Helen Athena Fulbright; Ana Isabel Duarte; Mark Crawford Simmonds

Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments. External Assessment Group Report

Pedro Rafael Saramago Goncalves, Mark Rodgers, Shainur Premji, Noortje Uphoff, Minyue Gao, Helen Athena Fulbright, Ana Isabel Duarte, Mark Crawford Simmonds

Research output: Book/Report › Commissioned report

Original language	English
Commissioning body	National Institute for Health and Care Excellence
Publication status	Published - 17 Oct 2023

Keywords

glofitamab
DLBCL

Access to Document

https://www.nice.org.uk/guidance/ta927/documents/committee-papers-2

Cite this

@book{2785f18c9c7f4fa9877104f2dfcdf09d,

title = "Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments.: External Assessment Group Report",

keywords = "glofitamab, DLBCL",

author = "{Saramago Goncalves}, {Pedro Rafael} and Mark Rodgers and Shainur Premji and Noortje Uphoff and Minyue Gao and Fulbright, {Helen Athena} and Duarte, {Ana Isabel} and Simmonds, {Mark Crawford}",

year = "2023",

month = oct,

day = "17",

language = "English",

}

TY - BOOK

T1 - Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments.

T2 - External Assessment Group Report

AU - Saramago Goncalves, Pedro Rafael

AU - Rodgers, Mark

AU - Premji, Shainur

AU - Uphoff, Noortje

AU - Gao, Minyue

AU - Fulbright, Helen Athena

AU - Duarte, Ana Isabel

AU - Simmonds, Mark Crawford

PY - 2023/10/17

Y1 - 2023/10/17

KW - glofitamab

KW - DLBCL

M3 - Commissioned report

BT - Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments.

ER -